Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: A study of the Hoosier Oncology Group

Hamid Sayar, Rebecca J. Chan, Christie M. Orschell, Edward M. Chan, Zhangsheng Yu, Daniel Hood, Artur Plett, Zhenyun Yang, Chua Lin Hui, Sarah C. Nabinger, Kristopher J. Kohlbacher, Evan S. West, Amanda Walter, Carol Sampson, Jingwei Wu, Larry D. Cripe

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Prolonged administration of methyl transferase inhibitors may increase response rates in myelodysplastic syndromes (MDS). Fourteen MDS patients with anemia and less than 10% marrow blasts received azacitidine 50mg/m 2 thrice weekly for 2 weeks every 4 weeks; 7 also received weekly erythropoietin. The response rate of 43% did not improve the rates reported with other azacitidine administration schedules, so the study was closed. A decreased apoptosis of primitive erythroid progenitors and increased expression of BclX L was observed with treatment in responding patients compared to non-responders. Azacitidine may modulate BclX L and improve erythropoiesis through reduction of apoptosis in primitive erythroid progenitor population in MDS.

Original languageEnglish (US)
Pages (from-to)1108-1110
Number of pages3
JournalLeukemia Research
Volume35
Issue number8
DOIs
StatePublished - Aug 1 2011

    Fingerprint

Keywords

  • Azacitidine
  • MDS
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Sayar, H., Chan, R. J., Orschell, C. M., Chan, E. M., Yu, Z., Hood, D., Plett, A., Yang, Z., Hui, C. L., Nabinger, S. C., Kohlbacher, K. J., West, E. S., Walter, A., Sampson, C., Wu, J., & Cripe, L. D. (2011). Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: A study of the Hoosier Oncology Group. Leukemia Research, 35(8), 1108-1110. https://doi.org/10.1016/j.leukres.2011.02.025